Opal Wealth Advisors LLC Has $295,000 Stake in Sanofi (NASDAQ:SNY)

Opal Wealth Advisors LLC grew its holdings in Sanofi (NASDAQ:SNY) by 11.7% during the third quarter, Holdings Channel.com reports. The firm owned 5,127 shares of the company’s stock after acquiring an additional 538 shares during the period. Opal Wealth Advisors LLC’s holdings in Sanofi were worth $295,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. POM Investment Strategies LLC acquired a new position in Sanofi during the 2nd quarter worth about $25,000. Register Financial Advisors LLC acquired a new position in shares of Sanofi during the first quarter worth approximately $29,000. Larson Financial Group LLC grew its stake in shares of Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares during the last quarter. Palisade Asset Management LLC acquired a new stake in shares of Sanofi in the first quarter valued at approximately $31,000. Finally, Arrow Financial Corp bought a new position in Sanofi in the 2nd quarter worth approximately $35,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Down 0.6 %

Shares of NASDAQ:SNY opened at $54.57 on Wednesday. The company has a 50 day moving average price of $55.95 and a two-hundred day moving average price of $51.44. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market capitalization of $138.21 billion, a PE ratio of 27.42, a PEG ratio of 1.56 and a beta of 0.60. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.95 EPS. Analysts forecast that Sanofi will post 4.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SNY shares. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday. Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.